These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9126702)

  • 21. Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools.
    Weinelt FA; Stegemann MS; Theloe A; Pfäfflin F; Achterberg S; Weber F; Dübel L; Mikolajewska A; Uhrig A; Kiessling P; Huisinga W; Michelet R; Hennig S; Kloft C
    Antibiotics (Basel); 2022 Jun; 11(6):. PubMed ID: 35740164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-Human Multiyear Evolution of Carbapenem-Resistant Klebsiella pneumoniae Causing Chronic Colonization and Intermittent Urinary Tract Infections: A Case Study.
    Kalu M; Tan K; Algorri M; Jorth P; Wong-Beringer A
    mSphere; 2022 Jun; 7(3):e0019022. PubMed ID: 35531657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenging T > MIC Using Meropenem vs.
    Nussbaumer-Pröll A; Eberl S; Kurdina E; Schmidt L; Zeitlinger M
    Front Pharmacol; 2022; 13():840692. PubMed ID: 35431957
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of the Acceptance of the Recommendations Made by a Meropenem Stewardship Program in a University Hospital: A Pilot Study.
    Alba Fernandez J; Del Pozo JL; Leiva J; Fernandez-Alonso M; Aquerreta I; Aldaz A; Blanco A; Yuste JR
    Antibiotics (Basel); 2022 Mar; 11(3):. PubMed ID: 35326793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing-A Translational Example for Intensive Care Units.
    Weinelt FA; Stegemann MS; Theloe A; Pfäfflin F; Achterberg S; Schmitt L; Huisinga W; Michelet R; Hennig S; Kloft C
    Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meropenem pharmacokinetics in critically ill patients with or without burn treated with or without continuous veno-venous haemofiltration.
    Selig DJ; Akers KS; Chung KK; Pruskowski KA; Livezey JR; Por ED
    Br J Clin Pharmacol; 2022 May; 88(5):2156-2168. PubMed ID: 34773921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
    Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
    Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Non-Enzymatic Degradation of Meropenem-Insights from the Bottle to the Body.
    Liebchen U; Rakete S; Vogeser M; Arend FM; Kinast C; Scharf C; Zoller M; Schönermarck U; Paal M
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34198482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients-A Controlled Clinical Trial.
    Simon P; Petroff D; Busse D; Heyne J; Girrbach F; Dietrich A; Kratzer A; Zeitlinger M; Kloft C; Kees F; Wrigge H; Dorn C
    Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33371322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptome-based design of antisense inhibitors potentiates carbapenem efficacy in CRE
    Aunins TR; Erickson KE; Chatterjee A
    Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30699-30709. PubMed ID: 33199638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study.
    Grensemann J; Busse D; König C; Roedl K; Jäger W; Jarczak D; Iwersen-Bergmann S; Manthey C; Kluge S; Kloft C; Fuhrmann V
    Ann Intensive Care; 2020 Apr; 10(1):48. PubMed ID: 32323030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness-Experience and Recommendations from One Year in Routine Clinical Practice.
    Scharf C; Paal M; Schroeder I; Vogeser M; Draenert R; Irlbeck M; Zoller M; Liebchen U
    Antibiotics (Basel); 2020 Mar; 9(3):. PubMed ID: 32245195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma and Renal Cortex Meropenem Concentrations in Patients Undergoing Percutaneous Renal Biopsy.
    Sepúlveda RA; Downey P; Soto D; Wong KY; Leung YC; So LY; Andresen M
    Biomed Res Int; 2019; 2019():1368397. PubMed ID: 31828087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
    Teng C; Baus C; Wilson JP; Frei CR
    Int J Med Sci; 2019; 16(11):1504-1509. PubMed ID: 31673242
    [No Abstract]   [Full Text] [Related]  

  • 35. Population pharmacokinetics of meropenem in critically ill children with different renal functions.
    Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M
    Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis.
    Verscheijden LFM; Koenderink JB; de Wildt SN; Russel FGM
    PLoS Comput Biol; 2019 Jun; 15(6):e1007117. PubMed ID: 31194730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A First-in-Human Study To Assess the Safety and Pharmacokinetics of LYS228, a Novel Intravenous Monobactam Antibiotic in Healthy Volunteers.
    Osborn M; Stachulski N; Sun H; Blais J; Venishetty V; Raccuglia M; Kankam M; Colvin R; Segal F
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fine-tuning carbapenem resistance by reducing porin permeability of bacteria activated in the selection process of conjugation.
    Kong HK; Pan Q; Lo WU; Liu X; Law COK; Chan TF; Ho PL; Lau TC
    Sci Rep; 2018 Oct; 8(1):15248. PubMed ID: 30323356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies.
    Germovsek E; Lutsar I; Kipper K; Karlsson MO; Planche T; Chazallon C; Meyer L; Trafojer UMT; Metsvaht T; Fournier I; Sharland M; Heath P; Standing JF;
    J Antimicrob Chemother; 2018 Jul; 73(7):1908-1916. PubMed ID: 29684147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
    Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.